Replies to post #490153 on NorthWest Biotherapeutics Inc (NWBO)

[monentum2play]

Plain and simple LP doesn't want any partners Even if will bring DCVAX faster to the markets.

[extrooper]

All Merck CEO & BOD know how to do is waste money on bs little add on junk companies and overpay themselves.

To actually make a difference , establish a new SOC for glioblastoma and possibly change all cancer therapy, DCVax costs them too much.

[DeeDee2]

DEEDEE2.
OCTOBER 17th, 2022 @ 1:30 PM Eastern time zone.

[biosectinvestor]

I hear you Red and unfortunately I don’t agree that manufacturing is holding anything up. Also, I don’t think that was the meaning of her words in them, for the situation now. I d not think they’d have given the presentation on manufacturing that they gave at ASCO if it were the hold-up. I also don’t think, even given the presentation, that they are far from having Flaskworks, 1.0 version ready for production, though I know some interpreted some asides as meaning that. I think that the more likely holdups would not be ultimately approval of Flaskworks for production but supply chain, which is a different issue and I don’t think it would currently hold-up marketing approval.

People assume a lot of things on bulletin boards and fill those ideas with great weight. But often they are not fundamentally true.

[pqr]

“No application without manufacturing capacity” attributed to LP. I am curious when this statement was reportedly made with regard to the purchase of FlaskWorks which was announced September 1, 2020. It would seem probable that LP was able to predict the material increase in capacity for a bespoke, autologous treatment, else it is hard to understand this as a policy decision rather than an aspirational goal. Red or anyone - can we identify the date of this reported declaration? This information would seem to bear upon whether comparability is or is not delaying anything. Tho, presumably, LP was not literally saying that application submissions would be delayed until FW is (hopefully) approved.